[1] 高婷, 李超, 梁锌, 等. 中国癌症流行的国际比较[J]. 中国肿瘤, 2016, 25(6): 409. doi: 10.3969/j.issn.1674-4136.2016.06.019
[2] 吴孟超, 汤钊猷, 刘允怡, 等. 原发性肝癌诊疗规范(2019年版)[J]. 中国实用外科杂志, 2020(2): 121.
[3] NG K, CHOK K, CHAN A, et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma[J]. Br J Surg, 2017, 104(13): 1775. doi: 10.1002/bjs.10677
[4] VIBERT E, SCHWARTZ M, OLTHOFF KM. Advances in resection and transplantation for hepatocellular carcinoma[J]. J Hepatol, 2020, 72(2): 262 doi: 10.1016/j.jhep.2019.11.017
[5] SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016, 10(1): 1. doi: 10.1007/s12072-015-9675-4
[6] LYU N, LIN Y, KONG Y, et al. FOXAI: a phase Ⅱ trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J]. Gut, 2018, 67(2): 395.
[7] LENCIONI R, DE BAERE T, SOULEN MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data[J]. Hepatology, 2016, 64(1): 106. doi: 10.1002/hep.28453
[8] LENG JJ, XU YZ, DONG JH. Efficacy of transarterial chemoembolization for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis[J]. ANZ J Surg, 2016, 86(10): 816. doi: 10.1111/ans.12803
[9] SI ZM, WANG GZ, QIAN S, et al. Combination therapies in the management of large(≥ 5 cm) hepatocellular carcinoma: microwave ablation immediately followed by transarterial chemoembolization[J]. J Vasc Interv Radiol, 2016, 27(10): 1577. doi: 10.1016/j.jvir.2016.02.014
[10] NI JY, KONG J, SUN HL, et al. Prognostic factors for survival after transarterial chemoembolization combined with sorafenib in the treatment of BCLC stage B and C hepatocellular carcinomas[J]. Acad Radiol, 2018, 25(4): 423. doi: 10.1016/j.acra.2017.10.018
[11] DUFFY AG, ULAHANNAN SV, MAKOROVA-RUSHER O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66(3): 545. doi: 10.1016/j.jhep.2016.10.029
[12] 解华, 刘宏杰, 李凌云, 等. 全身化疗联合肝动脉栓塞灌注化疗治疗乳腺癌肝转移的效果[J]. 蚌埠医学院学报, 2016, 41(11): 1474.
[13] 郑可心, 韩冰, 祁兴顺, 等. 《2018年美国肝病学会实践指导: 肝细胞癌的诊断、分期和管理》摘译[J]. 临床肝胆病杂志, 2018, 34(6): 1181. doi: 10.3969/j.issn.1001-5256.2018.06.009
[14] YJ J, JW L. Therapeutic priorities for solitary large hepatocellular carcinoma in a hepatitis B virus endemic area: an analysis of a nationwide cancer registry database[J]. J Surg Oncol, 2017, 115(4): 407. doi: 10.1002/jso.24519
[15] LEUNG U, KUK D, D'ANGELICA MI, et al. Long-term outcomes following microwave ablation for liver malignancies[J]. Br J Surg, 2015, 102(1): 85.
[16] CHEN QF, JIA ZY, YANG ZQ, et al. Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-microwave ablation therapy for hepatocellular carcinoma tumors ≤ 5 cm: a propensity analysis at a single center[J]. Cardiovasc Intervent Radiol, 2017, 40(11): 1748. doi: 10.1007/s00270-017-1736-8
[17] 谭骅, 仁虹, 赵玲, 等. 行TACE治疗后原发性肝细胞癌患者预后的影响因素[J]. 昆明医科大学学报, 2019, 40(3): 29.
[18] ZHENG L, LI HL, GUO CY, et al. Comparison of the efficacy and prognostic factors of transarterial chemoembolization plus microwave ablation versus transarterial chemoembolization alone in patients with a large solitary or multinodular hepatocellular carcinomas[J]. Korean J Radiol, 2018, 19(2): 237.